# A Study of Orelabrutinib in Patients With ITP

> **NCT05124028** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Orelabrutinib

## Key facts

- **NCT ID:** NCT05124028
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-01
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-06-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2021-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05124028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05124028, "A Study of Orelabrutinib in Patients With ITP". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT05124028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*